|
Characteristic
|
Adherence Status1
|
Crude hazard ratio [95 % CI]
|
p-value
|
Adjusted hazard ratio [95 % CI]
|
p-value
|
|---|
|
Adhered
|
Defaulted
|
|---|
|
Drug regimen
| | | | | | |
|
3TC/AZT −28 days
|
42
|
33
|
1.00
| |
1.00
| |
|
3TC/AZT-3 days
|
101
|
0
|
1.79 [1.25–2.56]
|
0.002
|
1.75 [1.16–2.66]
|
0.008
|
|
3TC/AZT/LPV-RTV −28 days
|
32
|
20
|
1.10 [0.69–1.74]
|
0.688
|
1.02 [0.56–1.88]
|
0.938
|
|
Gender
| | | | | | |
|
Female
|
102
|
29
|
1.00
| | | |
|
Male
|
73
|
24
|
0.97 [0.72–1.31]
|
0.824
|
-
|
-
|
|
Age range (years)
| | | | | | |
|
18–30
|
129
|
32
|
1.00
| | | |
|
31–40
|
34
|
16
|
0.85 [0.58–1.24]
|
0.395
| | |
|
41–50
|
6
|
4
|
0.75 [0.33–1.70]
|
0.489
| | |
|
>51
|
6
|
1
|
1.07 [0.47–2.43]
|
0.872
|
-
|
-
|
|
Risk assessment
| | | | | | |
|
Low
|
103
|
11
|
1.00
| |
1.00
| |
|
Medium
|
36
|
20
|
0.71 [0.49–1.04]
|
0.079
|
0.91 [0.60–1.39]
|
0.672
|
|
High
|
36
|
22
|
0.69 [0.47–1.00]
|
0.052
|
1.05 [0.56–2.00]
|
0.871
|
|
Type of exposure
| | | | | | |
|
Percutaneous
|
165
|
46
|
1.00
| | | |
|
Mucocutaneous
|
10
|
7
|
0.75 [0.40–1.42]
|
0.382
|
-
|
-
|
|
Profession
| | | | | | |
|
Nurses
|
65
|
17
|
1.00
| | | |
|
HCS
|
19
|
5
|
1.00 [0.60–1.67]
|
0.996
| | |
|
Laboratory Staff
|
9
|
7
|
0.71 [0.35–1.43]
|
0.335
| | |
|
Medical Doctors
|
59
|
18
|
0.97 [0.68–1.38]
|
0.850
| | |
|
Ward Attendants
|
23
|
6
|
1.00 [0.62–1.61]
|
0.998
|
-
|
-
|
- 1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval
